| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $9,629,723 | 13 | 100 |
| SATO VICKI L | director | 0 | $0 | 1 | $64,403 | $-64,403 |
| Schuth Alexander O. | COFO and Secretary | 0 | $0 | 3 | $348,175 | $-348,175 |
| Ho Carole | Chief Medical Officer | 0 | $0 | 4 | $359,975 | $-359,975 |
| Krognes Steve E. | director | 0 | $0 | 2 | $676,985 | $-676,985 |
| Watts Ryan J. | President and CEO | 0 | $0 | 3 | $8.18M | $-8.18M |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Denali Therapeutics Inc. have bought $0 and sold $9.63M worth of Denali Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Denali Therapeutics Inc. have bought $0 and sold $49.55M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 550,000 shares for transaction amount of $9.9M was made by BRATTON DOUGLAS K (10 percent owner) on 2017‑12‑12.
| 2025-08-13 | Sale | Ho Carole | Chief Medical Officer | 806 0.0005% | $14.64 | $11,800 | +4.46% | |
| 2025-08-12 | Sale | Schuth Alexander O. | COFO and Secretary | 2,937 0.002% | $13.58 | $39,884 | +16.87% | |
| 2025-08-12 | Sale | Ho Carole | Chief Medical Officer | 2,937 0.002% | $13.58 | $39,884 | +16.87% | |
| 2025-07-09 | Sale | Watts Ryan J. | President and CEO | 495,282 0.3409% | $15.00 | $7.43M | +1.33% | |
| 2025-01-07 | Sale | Watts Ryan J. | President and CEO | 7,650 0.0052% | $20.81 | $159,197 | -29.65% | |
| 2025-01-07 | Sale | Schuth Alexander O. | COFO and Secretary | 2,907 0.002% | $20.81 | $60,495 | -29.65% | |
| 2025-01-07 | Sale | Ho Carole | Chief Medical Officer | 2,907 0.002% | $20.81 | $60,495 | -29.65% | |
| 2025-01-07 | Sale | Krognes Steve E. | director | 3,339 0.0023% | $20.81 | $69,485 | -29.65% | |
| 2025-01-06 | Sale | Watts Ryan J. | President and CEO | 29,266 0.0208% | $20.22 | $591,759 | -24.80% | |
| 2025-01-06 | Sale | Schuth Alexander O. | COFO and Secretary | 12,255 0.0087% | $20.22 | $247,796 | -24.80% | |
| 2025-01-06 | Sale | Ho Carole | Chief Medical Officer | 12,255 0.0087% | $20.22 | $247,796 | -24.80% | |
| 2025-01-02 | Sale | SATO VICKI L | director | 3,080 0.0021% | $20.91 | $64,403 | -28.43% | |
| 2024-12-31 | Sale | Krognes Steve E. | director | 30,000 0.0207% | $20.25 | $607,500 | -26.79% | |
| 2024-11-11 | Sale | Schenkein David P | director | 59,441 0.0421% | $32.51 | $1.93M | -51.96% | |
| 2024-11-07 | Sale | Schuth Alexander O. | COFO and Secretary | 15,558 0.0109% | $29.91 | $465,286 | -48.67% | |
| 2024-11-07 | Sale | SATO VICKI L | director | 1,020 0.0007% | $30.00 | $30,600 | -48.67% | |
| 2024-11-01 | Sale | SATO VICKI L | director | 3,080 0.0022% | $27.07 | $83,376 | -43.73% | |
| 2024-10-18 | Sale | Watts Ryan J. | President and CEO | 40,000 0.028% | $27.69 | $1.11M | -44.84% | |
| 2024-09-30 | Sale | Krognes Steve E. | director | 30,000 0.0208% | $29.03 | $870,900 | -47.15% | |
| 2024-09-13 | Sale | SATO VICKI L | director | 1,020 0.0007% | $30.00 | $30,600 | -48.16% |
| Watts Ryan J. | President and CEO | 253071 0.1726% | $5.05M | 0 | 66 | |
| Schuth Alexander O. | COFO and Secretary | 242346 0.1652% | $4.84M | 0 | 70 | |
| Ho Carole | Chief Medical Officer | 216585 0.1477% | $4.32M | 0 | 66 | |
| SATO VICKI L | director | 107976 0.0736% | $2.16M | 0 | 28 | |
| Krognes Steve E. | director | 25757 0.0176% | $514,109.72 | 0 | 24 | |
| BRATTON DOUGLAS K | 10 percent owner | 9984836 6.8081% | $199.3M | 1 | 12 | <0.0001% |
| Tessier-Lavigne Marc | director | 1870356 1.2753% | $37.33M | 0 | 17 | |
| Cook Jennifer E. | director | 20038 0.0137% | $399,958.48 | 0 | 1 | |
| Schenkein David P | director | 9220 0.0063% | $184,031.20 | 0 | 5 |
$193,151,375 | 134 | 8.18% | $3.05B | |
$11,588,217 | 69 | 42.07% | $2.89B | |
$11,583,737 | 45 | 49.75% | $3.13B | |
$224,382,625 | 44 | 27.62% | $3.38B | |
$104,428,685 | 44 | 22.55% | $2.94B | |
$571,084,134 | 44 | 4.33% | $2.75B | |
$148,770,544 | 34 | 80.63% | $2.87B | |
$62,927,079 | 29 | 14.02% | $2.76B | |
$61,703,557 | 26 | 40.25% | $2.64B | |
$25,045,414 | 23 | -3.79% | $2.92B | |
$174,105,409 | 15 | 10.88% | $2.99B | |
$73,814,940 | 15 | -4.77% | $2.6B | |
$45,445,266 | 9 | -24.96% | $3.14B | |
$32,575,266 | 8 | 37.03% | $3.47B | |
$91,589,325 | 7 | -6.97% | $2.9B | |
$7,605,533 | 5 | 17.10% | $2.55B | |
$142,493,653 | 3 | 4.30% | $3.05B | |
$7,600,000 | 1 | -4.05% | $3.25B | |
Denali Therapeutics Inc. (DNLI) | $9,900,000 | 1 | -7.19% | $2.93B |
| Increased Positions | 129 | +54.89% | 20M | +14.47% |
| Decreased Positions | 95 | -40.43% | 16M | -11.52% |
| New Positions | 37 | New | 3M | New |
| Sold Out Positions | 23 | Sold Out | 1M | Sold Out |
| Total Postitions | 269 | +14.47% | 140M | +2.94% |
| Blackrock, Inc. | $239,279.00 | 8.36% | 12.29M | +236,281 | +1.96% | 2025-09-30 |
| Vanguard Group Inc | $233,502.00 | 8.16% | 11.99M | +182,183 | +1.54% | 2025-09-30 |
| Baillie Gifford & Co | $225,688.00 | 7.89% | 11.59M | -363,738 | -3.04% | 2025-09-30 |
| Fmr Llc | $123,446.00 | 4.31% | 6.34M | -1M | -15.89% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $109,783.00 | 3.84% | 5.64M | +2M | +73.66% | 2025-09-30 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Ame | $106,404.00 | 3.72% | 5.47M | -797,240 | -12.73% | 2025-09-30 |
| State Street Corp | $106,389.00 | 3.72% | 5.46M | +946,267 | +20.94% | 2025-09-30 |
| Temasek Holdings (Private) Ltd | $104,278.00 | 3.64% | 5.36M | 0 | 0% | 2025-09-30 |
| Capital Research Global Investors | $92,694.00 | 3.24% | 4.76M | +10,279 | +0.22% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $88,946.00 | 3.11% | 4.57M | -2M | -30.6% | 2025-09-30 |